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Timothy S. Fenske,1 Parameswaran N. Hari,2 Jeanette Carreras,2 Mei-Jie Zhang,2
Rammurti T. Kamble,3 Brian J. Bolwell,4 Mitchell S. Cairo,5 Richard E. Champlin,6
Yi-Bin Chen,7 Cesar O. Freytes,8 Robert Peter Gale,9 Gregory A. Hale,10 Osman Ilhan,11
H. Jean Khoury,12 John Lister,13 Dipnarine Maharaj,14 David I. Marks,15 Reinhold Munker,16
Andrew L. Pecora,17 Philip A. Rowlings,18 Thomas C. Shea,19 Patrick Stiff,20
Peter H. Wiernik,21 Jane N. Winter,22 J. Douglas Rizzo,2 Koen van Besien,23
Hillard M. Lazarus,24 Julie M. Vose25Incorporation of the anti-CD20monoclonal antibody rituximab into front-line regimens to treat diffuse large
B cell lymphoma (DLBCL) has resulted in improved survival. Despite this progress, however, many patients
develop refractory or recurrent DLBCL and then undergo autologous hematopoietic stem cell transplanta-
tion (AuHCT). It is unclear to what extent pre-transplant exposure to rituximab affects outcomes after
AuHCT. Outcomes of 994 patients receiving AuHCT for DLBCL between 1996 and 2003 were analyzed
according to whether rituximab was (n 5 176;1R cohort) or was not (n5 818;2R cohort) administered
with front-line or salvage therapy beforeAuHCT. The1R cohort had superior progression-free survival (PFS;
50% vs 38%; P5 .008) and overall survival (OS; 57% vs 45%; P5 .006) at 3 years. Platelet and neutrophil en-
graftmentwere not affected by exposure to rituximab.Nonrelapsemortality (NRM) did not differ significantly
between the 2 cohorts. In multivariate analysis, the1R cohort had improved PFS (relative risk of relapse/pro-
gression or death, 0.64; P\.001) and improved OS (relative risk of death, 0.74; P5 .039). We conclude that
pre-transplant rituximab is associatedwith a lower rate of progression and improved survival afterAuHCT for
DLBCL, with no evidence of impaired engraftment or increased NRM.
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ables [1]. Before the introduction of rituximab, the
probability of long-term survival ranged between 26%
and 73%, depending on the IPI [1]. With the addition
of rituximab to standard front-line chemotherapy, out-
comes have improved across all IPI groups [2-5].
For patients with relapsed chemosensitive
DLBCL, the Parma trial established high-dose chemo-
therapy and autologous hematopoietic cell transplan-
tation (AuHCT) as superior to conventional salvage
chemotherapy alone [6]. However that study was car-
ried out in the prerituximab era, making its relevance
in DLBCL patients treated with rituximab-containing
frontline or salvage regimens uncertain. It has been
reported that pre-transplant rituximab exposure may
affect outcomes after high-dose therapy and AuHCT.
For example, in one single-center retrospective study,
inclusion of rituximab in pre-transplant salvage therapy
was associated with improved survival and delayed
platelet engraftment in patients with intermediate-
grade B cell NHL undergoing AuHCT [7].
We hypothesized that pre-transplant exposure to
rituximab may affect outcomes after AuHCT for
DLBCL, including relapse/progression, survival, tox-
icity, and engraftment. Using the Center for Interna-
tional Blood and Transplant Research (CIBMTR)
database, we retrospectively compared outcomes in
rituximab-naı¨ve and rituximab-exposed adult patients
undergoing AuHCT for DLCBL.PATIENTS AND METHODS
Data Sources
A research affiliate of the International Bone Mar-
row Transplant Registry, the Autologous Blood and
Marrow Transplant Registry, and the National
Marrow Donor Program (NMDP), the CIBMTR is
a voluntary working group of more than 450 transplan-
tation centers worldwide that contribute detailed data
on consecutive allogeneic and autologous transplanta-
tions to a statistical center at the Health Policy
Institute of the Medical College of Wisconsin in
Milwaukee or the NMDP Coordinating Center in
Minneapolis. Participating centers are required to
report all consecutive transplantations; compliance is
monitored by onsite audits. Subjects are followed lon-
gitudinally, with yearly follow-up. Computerized
checks for errors, physicians’ review of submitted
data, and onsite audits of participating centers ensure
data quality. CIBMTR observational studies are con-
ducted with a waiver of informed consent and in com-
pliance with HIPAA regulations as determined by the
Institutional Review Board and the Privacy Officer of
the Medical College of Wisconsin.
The CIBMTR collects data at 2 levels: registration
and research. Registration data include disease type,age, sex, pre-transplant disease stage and chemotherapy
responsiveness, date of diagnosis, graft type (bone
marrow [BM]– and/or blood-derived stem cells),
high-dose conditioning regimen, posttransplantation
disease progression and survival, development of
a new malignancy, and cause of death. Requests for
data on progression or death for registered patients
are made at 6-month intervals. All CIBMTR teams
contribute registration data. Research data are col-
lected on a subset of registered patients selected using
a weighted randomization scheme and include detailed
disease and pre-transplant and posttransplantation
clinical information.
Patients
A total of 1155 patients who underwent AuHCT
for DLBCL between 1996 and 2003 were reported
to the CIBMTR database. Eight patients aged\ 18
years at transplantation and 11 patients receiving post-
transplantation rituximab for maintenance were ex-
cluded. Seventy-four patients who relapsed . 10
years after initial diagnosis, 56 patients with bone mar-
row grafts, and 12 patients who received rituximab as
part of the conditioning regimen also were excluded.
Thus, a total of 994 subjects were evaluated. Of these
subjects, 176 received rituximab before transplanta-
tion, as part of first-line therapy and/or salvage therapy
(the 1‘‘R’’ cohort), while 818 were rituximab-naı¨ve at
the time of transplantation (the 2‘‘R’’ cohort).
Study Endpoints
Outcomes analyzed included engraftment, nonre-
lapse mortality (NRM), relapse/progression, progres-
sion-free survival (PFS), and overall survival (OS).
NRM was defined as death occurring within 28 days
posttransplantation or death without progression of
lymphoma. Subjects with lymphoma progression
were censored at the time of progression, and a cumu-
lative incidence estimate was derived, with progression
or relapse as the competing risk. Progression/relapse
was defined as progressive lymphoma at $ 28 days
posttransplantation or recurrence of lymphoma. It
could follow a period of ‘‘stable’’ disease posttransplan-
tation or a partial remission (PR) or complete remis-
sion (CR). Progression/relapse represents new or
larger areas of lymphoma ($ 25% increase in largest
diameter) compared with the best posttransplantation
lymphoma state. Relapse/progression was summarized
by the cumulative incidence estimate, with NRM as
the competing risk. For PFS, subjects were considered
treatment failures at the time of lymphoma progres-
sion or death from any cause. Subjects alive without ev-
idence of lymphoma progression were censored at last
follow-up, and the PFS event was summarized by a sur-
vival curve. The OS interval variable was defined as
time from the date of transplantation to the date of
Biol Blood Marrow Transplant 15:1455-1464, 2009 1457Pretransplant rituximab and autologous HCToutcomedeath or last contact and was summarized by a survival
curve.Statistical Analysis
Subject-, disease-, and transplantation-related vari-
ables for the1R and2R cohorts were compared using
the c2 test for categorical variables and the Kruskal-
Wallis test for continuous variables. Univariate proba-
bilities of neutrophil and platelet recovery and NRM
were calculated using cumulative incidence curves to
accommodate corresponding competing risks [8].
Probabilities of OS and PFS were calculated using the
Kaplan-Meier estimator [9], and 95% confidence inter-
vals (CIs) were calculated with a log-transformation.
To compare the outcomes of NRM, progression/
relapse, PFS, and OS, a Cox proportional hazards
model was used to adjust for potential imbalance in
baseline characteristics between treatment cohorts.
A stepwise-forward method was used to identify cova-
riates that influenced outcomes. Each model contained
the main effect (rituximab vs no rituximab). Any cova-
riate with a P value # .05 was considered significant.
The proportionality assumption for Cox regression
was tested by adding a time-dependent covariate for
each risk factor and each outcome; the results indicated
that all variables except Karnofsky performance score
met the proportional hazards assumption. Cox regres-
sion models stratified on the Karnofsky score were
used for each outcome event. The final results are ex-
pressed as relative risk (RR) of the event and its 95%
CI. The following variables were considered in model
building: rituximab versus no rituximab (main effect),
age at transplantation, Karnofsky performance status
at transplantation, number of lines of chemotherapy,
BM involvement at transplantation, disease status at
transplantation, size of largest lymphoma mass before
transplantation, time from diagnosis to transplanta-
tion, conditioning regimen, year of transplantation,
and administration of granulocyte colony-stimulating
factor (G-CSF) or granulocyte macrophage colony-
stimulating factor (GM-CSF) within 7 days posttrans-
plantation. The main effect of interest, rituximab ver-
sus no rituximab, was retained in all steps of model
building. Potential interactions between the main ef-
fect and all significant risk factors were tested, with
no interactions detected for all significant risk factors.
All analyses were performed using SAS version 8.2
(SAS Institute, Cary NC).RESULTS
Patient Characteristics
Patient-, disease-, and transplantation-related
characteristics are summarized in Table 1. A total of
176 subjects received rituximab before transplantationduring first-line therapy and/or salvage therapy (the
1‘‘R’’ cohort), and 818 subjects were rituximab-naı¨ve
at the time of transplantation (the 2‘‘R’’ cohort).
The median follow-up of survivors was 44 months
for the 1R cohort and 62 months for the 2R cohort.
Follow-up was 90% complete.
The 1R cohort had a higher median age (58 vs 52
years; P\ .001) and a higher proportion of patients
aged 55 or older (55% vs 40%; P\ .001). The1R co-
hort also was more heavily pretreated before trans-
plantation, with a higher proportion of patients
receiving . 2 lines of chemotherapy (57% vs 40%; P
\ .001); however, this difference may be accounted
for to some extent by the fact that rituximab alone
was counted as a regimen. Rituximab was administered
with first-line chemotherapy in 38% of patients and
with salvage therapy only in 62% of patients, with no
patients receiving rituximab with both first-line and
salvage therapy. The cohorts were well matched for
disease status at transplantation, bulky disease, second
line age-adjusted IPI score, and BM involvement. In
addition, pre-transplant chemosensitivity and Ann
Arbor stage at transplant did not differ between the 2
cohorts.
The 1R and 2R cohorts underwent AuHCT at
similar intervals after diagnosis and received similar
conditioning regimens. As expected, transplantation
was performed between 1999 and 2003 in 96% of the
patients in the 1R cohort and between 1996 and
2001 in 93% of those in the 2R cohort (P\ .001).
A similar proportion of patients in each cohort
received myeloid growth factor posttransplantation.
The use of posttransplant radiation therapy also was
similar in the 2 cohorts.
Outcomes
Engraftment
The cumulative incidence of platelet and neutro-
phil engraftment at 28 and 100 days was similar in
the 2 cohorts (Figure 1). There was no clinically signif-
icant difference in the rate of neutrophil engraftment
(defined as an absolute neutrophil count [ANC]
. 0.5  109/L) or platelet engraftment (defined as
a platelet count of 20,000/mL with no transfusion re-
quirement) between the 2 cohorts. The patients who
received rituximab within 3 months of transplantation
(n 5 60) were analyzed separately for engraftment de-
lay. These patients also achieved neutrophil engraft-
ment by day 17 and had platelet recovery at a median
of 17 days, with no difference compared with the 2R
cohort (P 5 .23) (data not shown).
NRM/causes of death
The cumulative incidences of NRM at 1, 3, and 5
years did not differ significantly between the 2 cohorts
(P5 .06) (Figure 2). In multivariate analysis, older age
Table 1. Patient-, Disease-, and Transplantation Characteristics
+R Cohort 2R Cohort
Variable n Evaluable n (%) n Evaluable n (%) P Value*
Number of patients 176 818
Age, years, median (range) 176 58 (20-76) 818 52 (18-75) < .001
Age at transplantation, years 176 818 < .001
< 55 79 (45) 489 (60)
$ 55 97 (55) 329 (40)
Male sex 176 89 (51) 817 473 (58) .08
Pre-transplant Karnofsky score < 90 166 64 (39) 795 292 (37) .66
Second line age-adjusted IPI at transplantation 176 818 .27
Low 40 (23) 201 (25)
Low-intermediate 45 (25) 216 (26)
High-intermediate 17 (10) 113 (14)
High 2 (1) 16 (2)
Missing 72 (41) 272 (33)
Disease status at transplantation 176 761 .45
CR1 38 (22) 130 (17)
CR2+ 35 (20) 124 (16)
PIF-sensitive 32 (18) 152 (20)
PIF-resistant 12 (7) 43 (6)
Relapse-sensitive 45 (25) 256 (34)
Relapse-resistant 14 (8) 56 (7)
Number of previous lines of therapy 176 815 < .001
1 13 (8) 119 (15)
2 62 (35) 370 (45)
3 65 (37) 234 (29)
4 34 (19) 67 (8)
5 2 (1) 20 (2)
Timing of rituximab treatment: 176 NA —
With first-line chemotherapy only 66 (38)
With salvage therapy only 110 (62)
Chemosensitive disease at transplantation 173 784 .75
Sensitive 146 (84) 653 (83)
Marrow involvement at transplantation 172 3 (2) 752 37 (5) .06
Mass 5cm before transplantation cm 60 16 (27) 274 95 (35) .23
Disease stage at diagnosis 168 802 .10
I 21 (13) 88 (11)
II 27 (16) 190 (24)
III 54 (32) 195 (24)
IV 66 (39) 326 (41)
Interval from diagnosis to transplantation,
months, median (range)
176 14 (3-200) 818 13 (2-277) .46
Interval from diagnosis to transplantation, months 176 818 .75
<12 76 (43) 364 (45)
$ 12 100 (57) 454 (55)
Radiation therapy posttransplantation 176 24 (14) 810 124 (15) .57
Conditioning regimen 176 818 .18
TBI-based 27 (15) 114 (14)
BEAM and similar 102 (58) 522 (64)
CBV or similar 27 (15) 77 (9)
Bu-MEL/Bu-Cy 10 (6) 48 (6)
Others 10 (6) 57 (7)
Interval from last rituximab given to transplantation,
median (range), months
170 5 (1-34) NA —
Graft type 176 818 .47
Peripheral blood 165 (94) 754 (92)
Bone marrow + PBSCs 11 (6) 64 (8)
Year of transplantation 176 818 < .001
1996-1998 7 (4) 481 (59)
1999-2001 80 (45) 281 (34)
2002-2003 89 (51) 56 (7)
G-CSF or GM-CSF given within 7 days posttransplantation 176 159 (90) 818 710 (87) .20
Median follow-up of survivors, months 102 42 (2-83) 336 62 (1-116) —
NA indicates not applicable; PIF, primary induction failure; TBI, total body irradiation; BEAM, BCNU + etoposite + Ara-C + melphalan; CBV, cyclospha-
mide + BCNU + VP16; PBSCs, peripheral blood stem cells.
*The c2 test was used for discrete covariates; the Kruskal-Wallis test was used for continuous covariates.
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. 1 year from diagnosis (RR 5 1.68; P 5 .002) were
associated with higher risk of NRM. Pre-transplantrituximab did not affect NRM (P 5 .18) (Table 2).
Causes of death were similar in the 1R and 2R co-
horts, with 58%-60% of deaths from lymphoma and
Biol Blood Marrow Transplant 15:1455-1464, 2009 1459Pretransplant rituximab and autologous HCToutcome40%-42% of deaths from causes other than relapse
(Table 3).
Relapse/progression and PFS
The risk of relapse/progression was lower in the1R
cohort compared with the 2R cohort (RR 5 0.67;
P 5 .004). Other significant covariates associated with
higher risk of relapse/progression were older age ($ 55
years; RR51.36; P5 .002), lack of a CR or chemosensi-
tive status at transplantation (P\ .001), and 3 or more
lines of previous chemotherapy (RR5 1.71; P\ .001).
PFS was superior in the 1R cohort, resulting in
a lower risk of treatment failure from relapse/progres-
sion or death in this cohort (RR 5 0.64; P\ .001)
(Table 4; Figure 3). Pointwise estimates of PFS at
the 1- and 3-year time points for the 1R and 2R
cohorts were 62% versus 49% (P5 .002) and 50% ver-
sus 38% (P 5 .008), respectively. Other significant
covariates associated with improved PFS and lower
risk of treatment failure were age \ 55 years, first
CR at the time of transplantation, and fewer than 3
lines of previous chemotherapy (Table 4).
OS
OS was superior in the 1R cohort, with a lower
risk of mortality (RR 5 0.74; P 5 .039) (Table 5;
Figure 4). Pointwise estimates of OS at the 1- and 3-
year time points for the 1R and 2R cohorts were
68% versus 60% (P 5 .049) and 57% versus 45%
(P 5 .006), respectively. In multivariate analysis, age
\ 55 years, first CR at the time of transplantation,
fewer than 3 lines of chemotherapy, and later year of
transplantation were all associated with lower mortal-
ity and improved survival (Table 5).
Timing of rituximab
The average interval from last rituximab dose to
transplantation was 5 months. Analysis revealed noFigure 1. Cumulative incidence of neutrophil and platelet recovery after AuH
transplantation.significant differences in PFS (Figure 5A) or OS
(Figure 5B) between patients receiving rituximab
within 6 months of transplantation and those receiving
rituximab . 6 months before transplantation.DISCUSSION
The Parma trial remains the only published pro-
spective, randomized trial comparing salvage chemo-
therapy alone with AuHCT for relapsed DLBCL.
Based on that study, AuHCT has remained the stan-
dard of care for patients with chemosensitive relapsed
and refractory DLBCL [6]. The Parma trial predates
the introduction of rituximab into clinical practice; in
contrast, patients with DLBCL are now routinely
treated with rituximab as part of front-line and/or sub-
sequent therapy. As a result, the outcomes after
AuHCT for DLBCL in the rituximab era are not fully
known. Our results indicate that pre-transplant rituxi-
mab is not associated with impaired engraftment or
increased NRM. In addition, improved PFS and OS
were seen in the 1R cohort.
There are several possible explanations for our ob-
servation of enhanced PFS and OS after AuHCT in
the 1R cohort:
1. It is possible that the 1R cohort was a more favor-
able group based on baseline patient characteristics.
However, this seems unlikely because these patients
were actually older than those in the –R cohort.
Moreover, the 2 cohorts were very similar in terms
of IPI score at transplantation, disease status at
transplantation, performance status, stage, chemo-
sensitivity, and bulky disease.
2. The fact that the 1R cohort underwent transplan-
tation in later years than the 2R cohort also might
account for the better outomes in the 1R cohort.
However, this would be expected to influenceCT for DLBCL analyzed by whether or not rituximab was given before
Figure 2. Cumulative incidence of NRM after AuHCT for DLBCL analyzed by whether or not rituximab was given before transplantation.
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provements in supportive care over time), and
would not be expected to affect PFS (because
both cohorts received similar conditioning regi-
mens). There was no significant difference in
NRM between the 2 cohorts.
3. In theory, the better PFS and OS in the1R cohort
could result from the delayed activity of rituximab
received during salvage therapy. However, the aver-
age interval from the last rituximab dose to trans-
plantation was 5 months, and no significant
differences in 1-, 3-, or 5-year PFS or OS were
seen between patients receiving rituximab within
6 months of transplantation and those receiving rit-
uximab . 6 months before transplantation.
4. Pre-transplant rituximab might possibly sensitize
or alter specific effector cell populations, or affect
immune reconstitution in ways that lead to en-
hanced anti-lymphoma effects. Unfortunately,
posttransplant immune reconstitution data were
not uniformly collected from the patients in this
study, precluding further testing of this hypothesis.Table 2. Multivariate Analyses for NRM*
Variables n
RR of NRM
(95% CI) P Value
Main effect
No rituximab 812 1.00
Rituximab 174 0.70 (0.41-1.18) .18
Other significant covariates
Age at transplantation, years
<55 562 1.00
$ 55 424 1.79 (1.31-2.45) < .001
Time from diagnosis to
transplantation, years
#1 435 1.00
>1 551 1.68 (1.21-2.34) .002
Year of transplantation
1996-1999 728 1.00
2000-2003 258 0.63 (0.40-1.00) .05
NRM indicates nonrelapse mortality.
*Cox models stratified on Karnofsky performance score.5. Finally, it is known that inclusion of rituximab in
first-line therapy has improved the outcome of spe-
cific subsets of DLBCL, such as those which are
bcl6-negative, bcl2-positive, or of nongerminal cen-
ter origin [10-12]. As a result, there could be impor-
tant biological differences between our1R and2R
cohorts that might account for the improved out-
come of the 1R cohort after AuHCT.
Although several cases of delayed neutropenia as-
sociated with rituximab have been described [13,14],
the stem cell yield after rituximab therapy appears to
be unaffected [7,15]. An additional concern is that
pre-transplantation rituximab may affect engraftment
kinetics [7]. Our findings support the concept that
pre-transplant exposure to rituximab does not com-
promise peripheral blood stem cell (PBSC) product
quality or engraftment.
One might expect a priori that patients with
relapsed or refractory DLBCL already exposed to rit-
uximab will be more likely to have rituximab-refrac-
tory disease, and thus also will be inherently more
difficult to rescue with rituximab-containing salvage
therapy followed by AuHCT. But, our data appear to
contradict this notion; those patients previously ex-
posed to rituximab actually had improved PFS and OS.
It is possible that the outcomes after AuHCT may
differ, depending on the exact timing of exposure toTable 3. Causes of Death before Day 100
+R Cohort -R Cohort
Cause of death n Evaluable n (%) n Evaluable n (%)
Number of patients 24 114
Relapse/progression 14 (58) 68 (60)
Other causes 10 (42) 46 (40)
Pulmonary syndrome 2 (8) 10 (9)
Infection 2 (8) 11 (9)
Organ failure 3 (14) 19 (17)
Hemorrhage 1 (4) 4 (3)
New malignancy 1 (4) 1 (1)
Unknown 1 (4) 1 (1)
Figure 3. Probability of PFS after AuHCT for DLBCL analyzed by whether or not rituximab was given before transplantation.
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therapy). The number of patients in the 1R cohort
was not sufficient to allow for meaningful subgroup
analysis based on rituximab exposure during first-line
therapy or salvage therapy, so our study does not shed
light on this issue. In a recently published study from
the Gruppo Italiano Terapie Innnovative nei Linfomi,
the benefit of rituximab before AuHCT was most ap-
parent in the patients with follicular lymphoma and
DLBCL who received rituximab with salvage therapy
but not with first-line therapy [16]. In a much smaller
study from Germany, an improved outcome after
AuHCT for aggressive NHL was associated with the
addition of rituximab to salvage therapy. In that study,
patients were largely (87%) rituximab-naı¨ve beforeTable 4. Multivariate Analysis for PFS*
Variables n
RR of Relapse/
Progression
or Death (95% CI) P Value
Main effect
No rituximab 812 1.00
Rituximab 174 0.64 (0.50-0.81) < .001
Other significant covariates
Age at transplantation, years
< 55 562 1.00
$ 55 424 1.45 (1.23-1.71) < .001
Disease status at transplantation
CR1 167 1.00 < .001†
PIF-sensitive 182 1.24 (0.91-1.69) .18
PIF-resistant 54 3.38 (2.30-4.96) < .001
Relapse-sensitive 298 2.02 (1.53-2.67) < .001
Relapse-resistant 69 2.65 (1.83-3.82) < .001
CR2+ 158 1.57 (1.14-2.14) .010
Unknown 58 2.13 (1.45-3.15) .001
Number of lines of chemotherapy
# 2 561 1.00 < .001‡
> 2 418 1.61 (1.36-1.91) < .001
PFS indicates progression-free survival; RR, relative risk; PIF, pulmonary
induction failure; CR, complete remission.
*Cox models stratified on Karnofsky performance score.
†Six degrees of freedom.
‡Two degrees of freedom.salvage therapy [17]. Ashraf et al. [18] recently reported
single-center outcomes of 63 patients with DLBCL
who underwent AuHCT between 1991 and 2008.
Similar to our findings, significantly better disease con-
trol after AuHCT was seen in the patients who received
rituximab as part of front-line therapy. In the ongoing
CORAL (Collaborative Trial in Relapsed Aggressive
Lymphoma) Study, relapsed and refractory CD20-
positive DLBCL patients are randomized between 2
different rituximab-based salvage chemotherapy regi-
mens, followed by AuHCT and then a second random-
ization of observation versus maintenance rituximab
[19]. The CORAL Study enrolls both patients with
and without rituximab in first-line therapy and onTable 5. Multivariate Analysis for OS*
Variable n
RR of Death
(95% CI) P Value
Main effect
No rituximab 818 1.00
Rituximab 176 0.74 (0.56-0.99) .039
Other significant covariates
Age at transplantation, years
< 55 568 1.00
$ 55 426 1.53 (1.29-1.83) < .001
Disease status at transplantation
CR1 168 1.00 < .001†
PIF-sensitive 184 1.29 (0.91-1.82) .15
PIF-resistant 54 3.23 (2.14-4.87) < .001
Relapse-sensitive 301 2.06 (1.51-2.81) < .001
Reapse-resistant 69 2.57 (1.73-3.83) < .001
CR2+ 159 1.58 (1.12-2.24) .010
Unknown 59 2.27 (1.50-3.44) < .001
Number of lines of chemotherapy
# 2 564 1.00 < .001‡
> 2 422 1.53 (1.28-1.82) < .001
Year of transplantation
1996-1999 735 1.00
2000-2003 259 0.73 (0.57-0.94) .013
OS indicates overall survival; RR, relative risk; PIF, pulmonary induction
failure; CR, complete remission.
*Cox models stratified on Karnofsky performance score.
†Six degrees of freedom.
‡Two degrees of freedom.
Figure 4. Probability of OS after AuHCT for DLBCL analyzed by whether or not rituximab was given before transplantation.
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rituximab exposure at different time points before
transplantation.
The patient cohorts in the present study are repre-
sentative of a period of transition in practice when the
use of rituximab was increasingly being used to treatFigure 5. A, Probability of PFS after AuHCT for DLBCL analyzed by whethe
plantation. B, Probability of OS after AuHCT for DLBCL analyzed by whetherDLBCL. Thus, a contemporary cohort of patients
who were rituximab-naı¨ve at the time of AuHCT was
available for comparison with the 1R cohort. In the
context of current clinical practice in the United States,
rituximab is generally used in both first-line and subse-
quent therapies for DLBCL; thus, it is highly unlikelyr or not rituximab was given\ 6 months or $ 6 months before trans-
rituximab was given\6 months or$ 6 months before transplantation.
Biol Blood Marrow Transplant 15:1455-1464, 2009 1463Pretransplant rituximab and autologous HCToutcomethat current AuHCT recipients for DLBCL will be rit-
uximab-naive. Nonetheless, our findings provide post hoc
validation for this practice and confirm the safety of pre-
vious rituximab therapy in the AuHCT setting.
In this study, with a median of 42 months of follow-
up in the1R cohort, there were only a small number of
patients with 5 or more years of follow-up. Thus, it was
not possible to perform statistically significant analyses
of longer-term survival outcomes beyond those
reported here. The magnitude of the benefit of pre-
transplant rituximab beyond 5 years after AuHCT re-
mains uncertain. Longer follow-up would help clarify
whether rituximab only serves to delay DLBCL relapse
or whether it leads to a higher rate of long-term disease-
free survival. The question of whether post-AuHCT
‘‘maintenance’’ therapy (using rituximab and/or other
agents) may offer a benefit for patients with DLBCL
also remains unanswered. Long-term data from ran-
domized trials, such as the ongoing CORAL Study,
are needed to further address these questions.ACKNOWLEDGMENTS
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